C. Annunziata, R. Davis, Y. Demchenko, W. Bellamy, A. Gabrea et al., Frequent Engagement of the Classical and Alternative NF-??B Pathways by Diverse Genetic Abnormalities in Multiple Myeloma, Cancer Cell, vol.12, issue.2, pp.115-145, 2007.
DOI : 10.1016/j.ccr.2007.07.004

A. Badros, A. Burger, S. Philip, R. Niesvizky, S. Kolla et al., Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma, Clinical Cancer Research, vol.15, issue.16, pp.5250-5257, 2009.
DOI : 10.1158/1078-0432.CCR-08-2850

M. Bantscheff, C. Hopf, M. Savitski, A. Dittmann, P. Grandi et al., Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes, Nature Biotechnology, vol.276, issue.3, pp.255-65, 2011.
DOI : 10.1038/nprot.2007.202

P. Bergsagel and W. Kuehl, Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma, Journal of Clinical Oncology, vol.23, issue.26, pp.6333-6341, 2005.
DOI : 10.1200/JCO.2005.05.021

L. Catley, E. Weisberg, Y. Tai, P. Atadja, S. Remiszewski et al., NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma, Blood, vol.102, issue.7, pp.2615-2637, 2003.
DOI : 10.1182/blood-2003-01-0233

C. Choudhary, C. Kumar, F. Gnad, M. Nielsen, M. Rehman et al., Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions, Science, vol.325, issue.5942, pp.834-874, 2009.
DOI : 10.1126/science.1175371

X. Cui and G. Churchill, Statistical tests for differential expression in cDNA microarray experiments, Genome Biology, vol.4, issue.4, p.210, 2003.
DOI : 10.1186/gb-2003-4-4-210

S. Derenne, B. Monia, N. Dean, J. Taylor, M. Rapp et al., Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells, Blood, vol.100, issue.1, pp.194-203, 2002.
DOI : 10.1182/blood.V100.1.194

M. J. Dimopoulos and S. Yoon, Vantage 088: vorinostat in combination with bortezomib in pa-tients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial, Blood, issue.118 811, 2011.

R. Feng, H. Ma, C. Hassig, J. Payne, N. Smith et al., KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling, Molecular Cancer Therapeutics, vol.7, issue.6, pp.1494-505, 2008.
DOI : 10.1158/1535-7163.MCT-08-0183

Z. Gu, J. Vos, C. Rebouissou, J. M. Zhang, X. Rossi et al., Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors, Leukemia, vol.14, issue.1, pp.188-97, 2000.
DOI : 10.1038/sj.leu.2401632

W. Hahn and R. Weinberg, Rules for Making Human Tumor Cells, New England Journal of Medicine, vol.347, issue.20, pp.1593-603, 2002.
DOI : 10.1056/NEJMra021902

S. Harrison, H. Quach, E. Link, J. Seymour, D. Ritchie et al., A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma, Blood, vol.118, issue.24, pp.6274-83, 2011.
DOI : 10.1182/blood-2011-03-339879

M. Hartl, A. Nist, M. Khan, T. Valovka, and K. Bister, Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1), Proceedings of the National Academy of Sciences, vol.106, issue.14, pp.5604-5613, 2009.
DOI : 10.1073/pnas.0812101106

G. Heller, W. Schmidt, B. Ziegler, S. Holzer, L. Mullauer et al., Genome-Wide Transcriptional Response to 5-Aza-2'-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells, Cancer Research, vol.68, issue.1, pp.44-54, 2008.
DOI : 10.1158/0008-5472.CAN-07-2531

T. Hideshima and K. Anderson, Histone deacetylase inhibitors in the treatment for multiple myeloma, International Journal of Hematology, vol.70, issue.3, pp.324-356, 2013.
DOI : 10.1007/s12185-013-1290-3

T. Hideshima, P. Bergsagel, W. Kuehl, and K. Anderson, Advances in biology of multiple myeloma: clinical applications, Blood, vol.104, issue.3, pp.607-625, 2004.
DOI : 10.1182/blood-2004-01-0037

T. Hideshima, P. Richardson, and K. Anderson, Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma, Molecular Cancer Therapeutics, vol.10, issue.11, pp.2034-2076, 2011.
DOI : 10.1158/1535-7163.MCT-11-0433

S. Iwahashi, M. Shimada, T. Utsunomiya, Y. Morine, S. Imura et al., Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis, Oncol Rep, vol.26, issue.5, pp.1057-62, 2011.

M. Jourdan, J. Veyrune, J. Vos, N. Redal, G. Couderc et al., A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells, Oncogene, vol.22, issue.19, pp.2950-2959, 2003.
DOI : 10.1038/sj.onc.1206423

URL : https://hal.archives-ouvertes.fr/inserm-00130855

S. Kahali, B. Sarcar, and P. Chinnaiyan, The Emerging Role of Histone Deacetylases (HDACs) in UPR Regulation, Methods in enzymology, vol.490, pp.159-74, 2011.
DOI : 10.1016/B978-0-12-385114-7.00010-6

S. Kahali, B. Sarcar, A. Prabhu, E. Seto, and C. , Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response, The FASEB Journal, vol.26, issue.6, pp.2437-2482
DOI : 10.1096/fj.11-193706

M. Kaiser, I. Zavrski, J. Sterz, C. Jakob, C. Fleissner et al., The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma, Haematologica, vol.91, issue.2, pp.248-51, 2006.

A. Kassambara, D. Hose, J. Moreaux, T. Reme, J. Torrent et al., Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma, PLoS ONE, vol.7, issue.7, 2012.
DOI : 10.1371/journal.pone.0042161.s007

URL : https://hal.archives-ouvertes.fr/inserm-00802686

A. Kassambara, D. Hose, J. Moreaux, B. Walker, A. Protopopov et al., Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma, Haematologica, vol.97, issue.4, pp.622-652, 2012.
DOI : 10.3324/haematol.2011.046821

URL : https://hal.archives-ouvertes.fr/inserm-00727008

J. Keats, R. Fonseca, M. Chesi, R. Schop, A. Baker et al., Promiscuous Mutations Activate the Noncanonical NF-??B Pathway in Multiple Myeloma, Cancer Cell, vol.12, issue.2, pp.131-175, 2007.
DOI : 10.1016/j.ccr.2007.07.003

T. Kelly, D. Carvalho, D. Jones, and P. , Epigenetic modifications as therapeutic targets, Nature Biotechnology, vol.7, issue.10, pp.1069-1078, 2010.
DOI : 10.1038/sj.bjc.6605293

S. Khan, T. Maududi, K. Barton, J. Ayers, and S. Alkan, Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma, British Journal of Haematology, vol.265, issue.2, pp.156-61, 2004.
DOI : 10.1093/jnci/90.21.1621

A. Lane and B. Chabner, Histone Deacetylase Inhibitors in Cancer Therapy, Journal of Clinical Oncology, vol.27, issue.32, pp.5459-68, 2009.
DOI : 10.1200/JCO.2009.22.1291

D. Larocque, A. Galarneau, H. Liu, M. Scott, G. Almazan et al., Protection of p27Kip1 mRNA by quaking RNA binding proteins promotes oligodendrocyte differentiation, Nature Neuroscience, vol.36, issue.1, pp.27-33, 2005.
DOI : 10.1016/S0014-4886(03)00101-8

D. Lavelle, Y. Chen, M. Hankewych, and J. Desimone, Histone deacetylase inhibitors increase p21WAF1 and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression, American Journal of Hematology, vol.81, issue.3, pp.170-178, 2001.
DOI : 10.1002/ajh.1174

K. Mahtouk, J. M. , D. Vos, J. Hertogh, C. Fiol et al., An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis, Blood, vol.103, issue.5, pp.1829-1866, 2004.
DOI : 10.1182/blood-2003-05-1510

URL : https://hal.archives-ouvertes.fr/inserm-00130207

C. Mitsiades, N. Mitsiades, C. Mcmullan, V. Poulaki, R. Shringarpure et al., Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications, Proceedings of the National Academy of Sciences, vol.101, issue.2, pp.540-545, 2004.
DOI : 10.1073/pnas.2536759100

N. Mitsiades, C. Mitsiades, P. Richardson, C. Mcmullan, V. Poulaki et al., Molecular sequelae of histone deacetylase inhibition in human malignant B cells, Blood, vol.101, issue.10, pp.4055-62, 2003.
DOI : 10.1182/blood-2002-11-3514

P. Moreau, The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies, Seminars in Hematology, vol.49, issue.1, pp.33-46, 2012.
DOI : 10.1053/j.seminhematol.2012.05.004

J. Moreaux, B. Klein, R. Bataille, G. Descamps, S. Maiga et al., A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, issue.4, pp.574-82, 2011.
DOI : 10.3324/haematol.2010.033456

URL : https://hal.archives-ouvertes.fr/inserm-00550232

J. Moreaux, T. Reme, W. Leonard, J. Veyrune, G. Requirand et al., Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors, Molecular Cancer Therapeutics, vol.11, issue.12, pp.2685-92, 2012.
DOI : 10.1158/1535-7163.MCT-12-0721

URL : https://hal.archives-ouvertes.fr/inserm-00760269

G. Morgan, B. Walker, and F. Davies, The genetic architecture of multiple myeloma, Nature Reviews Cancer, vol.214, issue.5, pp.335-383, 2012.
DOI : 10.1038/nrc3257

P. Neri, N. Bahlis, and S. Lonial, Panobinostat for the treatment of multiple myeloma, Expert Opinion on Investigational Drugs, vol.289, issue.15, pp.733-780, 2012.
DOI : 10.1073/pnas.0913912107

P. Neri, P. Tagliaferri, D. Martino, M. Calimeri, T. Amodio et al., In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor, Br J Haematol, vol.143, issue.4, pp.520-551, 2008.

M. Niesen and G. Blanck, Rescue of Major Histocompatibility-DR Surface Expression in Retinoblastoma-Defective, Non-small Cell Lung Carcinoma Cells by the MS-275 Histone Deacetylase Inhibitor, Biological & Pharmaceutical Bulletin, vol.32, issue.3, pp.480-482, 2009.
DOI : 10.1248/bpb.32.480

R. Niesvizky, S. Ely, T. Mark, S. Aggarwal, J. Gabrilove et al., Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma, Cancer, vol.112, issue.2, pp.336-378, 2011.
DOI : 10.1002/cncr.25584

M. Offidani, C. Polloni, F. Cavallo, A. Liberati, S. Ballanti et al., Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma, Leukemia & Lymphoma, vol.96, issue.2, pp.1722-1729, 2012.
DOI : 10.1016/j.cell.2007.01.029

R. Rao, S. Nalluri, R. Kolhe, Y. Yang, W. Fiskus et al., Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells, Molecular Cancer Therapeutics, vol.9, issue.4, pp.942-52, 2010.
DOI : 10.1158/1535-7163.MCT-09-0988

C. Rebouissou, J. Wijdenes, P. Autissier, K. Tarte, V. Costes et al., A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma, Blood, vol.91, issue.12, pp.4727-4764, 1998.

T. Reme, D. Hose, D. Vos, J. Vassal, A. Poulain et al., A new method for class prediction based on signed-rank algorithms applied to Affymetrix?? microarray experiments, BMC Bioinformatics, vol.9, issue.1, p.16, 2008.
DOI : 10.1186/1471-2105-9-16

URL : https://hal.archives-ouvertes.fr/inserm-00268075

P. Richardson, C. Mitsiades, K. Colson, E. Reilly, L. Mcbride et al., Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma, Leukemia & Lymphoma, vol.49, issue.3, pp.502-509, 2008.
DOI : 10.1158/1078-0432.CCR-03-0561

P. Richardson, . Am, and D. Weber, Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomibrefractory multiple myeloma (PANORAMA 2) Blood 1 1 8 : a b s t r a c t 8 1 4 ; o r a l presentation, 2011.

A. Rio-machin, B. Ferreira, T. Henry, G. Gomez-lopez, X. Agirre et al., Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype, Leukemia, vol.91, issue.4, pp.925-956, 2013.
DOI : 10.1002/hep.23660

J. San-miguel, . Dmhv, and S. Yoon, Update on a phase III study of panobinostat with bort-ezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1, Blood, vol.118, p.3976, 2011.

J. San-miguel, . So, and D. Siegel, A phase IB, multi-center, open-label dose-escalation study of oral panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma, Blood, vol.114, p.3852, 2009.

A. Shaffer, N. Emre, L. Lamy, V. Ngo, G. Wright et al., IRF4 addiction in multiple myeloma, Nature, vol.403, issue.7201, pp.226-257, 2008.
DOI : 10.1038/nature07064

D. Siegel, . Dm, S. Yoon, and J. Laubach, Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial, Blood, issue.114, p.480, 2011.

D. Siegel, . So, and J. San-miguel, A phase IB, multicenter, open-label, dose-escalation study of oral panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma, Blood, vol.112, p.2781, 2008.

A. Skopelitou, M. Hadjiyannakis, A. Tsenga, S. Theocharis, V. Alexopoulou et al., Expression of C-myc p62 oncoprotein in multiple myeloma: an immunohistochemical study of 180 cases, Anticancer Res, vol.13, issue.4, pp.1091-1096, 1993.

T. Le-carrour, S. , S. Tondeur, L. Lhermitte, N. Lamb et al., Amazonia!: An Online Resource to Google and Visualize Public Human whole Genome Expression Data, The Open Bioinformatics Journal, vol.4, issue.1, pp.5-10, 2010.
DOI : 10.2174/1875036201004010005

K. Tarte, X. Zhang, E. Legouffe, C. Hertog, M. Mehtali et al., Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells, J Immunol, vol.163, issue.1, pp.514-538, 1999.

G. Totzke, F. Essmann, S. Pohlmann, C. Lindenblatt, R. Janicke et al., A Novel Member of the I??B Family, Human I??B-??, Inhibits Transactivation of p65 and Its DNA Binding, Journal of Biological Chemistry, vol.281, issue.18, pp.12645-54, 2006.
DOI : 10.1074/jbc.M511956200

B. Vogelstein and K. Kinzler, Cancer genes and the pathways they control, Nature Medicine, vol.1, issue.8, pp.789-99, 2004.
DOI : 10.1038/sj.onc.1207130

J. Wolf, D. Siegel, H. Goldschmidt, K. Hazell, P. Bourquelot et al., Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma, Leukemia & Lymphoma, vol.29, issue.9, pp.1820-1823, 2012.
DOI : 10.1002/cncr.25584

Z. Wu, X. Zhang, Y. J. Wu, G. Zhang, Y. Yuan et al., Nuclear protein I??B-?? inhibits the activity of STAT3, Biochemical and Biophysical Research Communications, vol.387, issue.2, pp.348-52, 2009.
DOI : 10.1016/j.bbrc.2009.07.023

W. Xiong, X. Wu, S. Starnes, S. Johnson, J. Haessler et al., An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma, Blood, vol.112, issue.10, pp.4235-4281, 2008.
DOI : 10.1182/blood-2007-10-119123

S. Yamazaki, T. Muta, and K. Takeshige, A Novel I??B Protein, I??B-??, Induced by Proinflammatory Stimuli, Negatively Regulates Nuclear Factor-??B in the Nuclei, Journal of Biological Chemistry, vol.276, issue.29, pp.27657-62, 2001.
DOI : 10.1074/jbc.M103426200

G. Yang, H. Fu, J. Zhang, X. Lu, F. Yu et al., RNA-Binding Protein Quaking, a Critical Regulator of Colon Epithelial Differentiation and a Suppressor of Colon Cancer, Gastroenterology, vol.138, issue.1, pp.231-271, 2010.
DOI : 10.1053/j.gastro.2009.08.001

G. Yang, X. Lu, L. Wang, Y. Bian, H. Fu et al., E2F1 and RNA binding protein QKI comprise a negative feedback in the cell cycle regulation, Cell Cycle, vol.10, issue.16, pp.2703-2716, 2011.
DOI : 10.4161/cc.10.16.15928

M. Yoshida, M. Kijima, M. Akita, and T. Beppu, Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A, J Biol Chem, vol.265, issue.28, pp.17174-17183, 1990.

F. Zhan, Y. Huang, S. Colla, J. Stewart, I. Hanamura et al., The molecular classification of multiple myeloma, Blood, vol.108, issue.6, pp.2020-2028, 2006.
DOI : 10.1182/blood-2005-11-013458

X. Zhang, J. Gaillard, N. Robillard, Z. Lu, Z. Gu et al., Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma, Blood, vol.83, issue.12, pp.3654-63, 1994.